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Abstract: Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated 
with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months. 
However, the discovery of KIT and platelet derived growth factor receptor alpha (PDGFRA) mutations as oncogenic drivers of most 
gastrointestinal tumours, paved the way for targeted therapy. Imatinib mesylate, a tyrosine kinase inhibitor, produces a clinical benefit 
rate (complete response, partial response, and stable disease) of more than 80% in metastatic setting and a median survival of 57 months. 
Imatinib is now also approved in adult patients following resection of KIT-positive GIST. Major insights into the mechanism of action 
of imatinib, unique pharmacokinetics, drug resistance, and management of low grade but chronic adverse effects continue to be made.
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Introduction
Gastrointestinal stromal tumours (GIST) are the most 
common mesenchymal neoplasms, with an incidence 
of 14.5 cases per million.1 While most GIST occur in 
the stomach (50%) or small bowel (25%), a minority 
are esophageal (5%) or colorectal (10%) in location.2 
The median age at diagnosis is 58 years and pediatric 
cases account for only 2% of all GIST.3,4 Pediatric 
GIST are characterized by female prevalence,   multiple 
gastric tumours, and wild type KIT and PDGFRA 
  genotype.4 Despite complete surgical removal of all 
macroscopic disease, 5 year disease free survival is 
about  45%.53  Chemotherapy  for  advanced  disease 
(typically  doxorubicin  based)  has  limited  efficacy 
with response rates of 0%–10% and median survival 
of 18 months.5,6 In comparison, the phase II B2222 
study examining two dose levels of imatinib mesylate 
(Glivec; Novartis Pharma AG, Basel, Switzerland) in 
unresectable or metastatic patients, reported a median 
overall survival of 57 months.7
Mechanism of Action
KIT, a member of the type III receptor tyrosine kinase 
(RTK)  family,  is  structurally  similar  to  platelet-
  derived  growth  factor  alpha  (PDGFA),  colony 
stimulating  factor-1  receptor  (CSF1R),  and  fms-
related receptor (FLT3).8 KIT is important for the 
development  of  melanocytes,  germ  cells,  mast 
cells,  hematopoietic  stem  cells,  and  the  intersti-
tial  cells  of  Cajal  (the  so-called  pacemaker  cells 
of  the  gastrointestinal  tract  that  GIST  cells  most 
closely resemble).9 The KIT transmembrane recep-
tor is composed of an extracellular region with five 
immunoglobulin-like domains (the second and third 
domain are involved in ligand recognition), a trans-
membrane hinge, a   juxta-membrane domain (JM), 
and a cytoplasmic region with two tyrosine domains. 
The  proximal  kinase  domain  anchors  ATP  while 
the distal kinase domain binds and phosphorylates 
downstream  substrates;  importantly,  an  activation 
loop which stabilizes the activated KIT receptor, is 
localized to the distal kinase. Binding of stem cell 
factor to KIT results in prompts receptor homodi-
merization,  activation  of  tyrosine  kinase  activity, 
and  stimulation  of  signal  transduction  pathways 
such as the Ras/Raf/mitogen activated protein kinase 
(MAPK),  phosphatidylinositol  3-kinase  (PI3K)/
Akt/mammalian target of rapamycin (mTOR), and 
Src  kinase    pathways.  The  net  result  is  cell  cycle 
activation, proliferation, and inhibition of apoptosis.
A  seminal  paper  by  Hirota  and  colleagues  in 
1998 made a number of pivotal discoveries: GIST 
express KIT protein, 5 of 6 tumor specimens had KIT 
mutations, and KIT mutations resulted in constitutive 
kinase activity.10 Further work clarified that KIT con-
tains 21 exons; mutations are most commonly located 
in exon 11 (70%) which encodes the juxtamembrane 
domain, exon 9 (13%) which encodes the fifth extra-
cellular  immunoglobulin-like  region,  and  less  fre-
quently in the tyrosine kinase domain 1 encoded by 
exon  13  (1%)  and  the  phosphotransferase  domain 
encoded by exon 17 (1%). Approximately 5% to 7% 
of GIST harbour oncogenic mutations in PDGFRA, 
typically in the juxtamembrane domain (exon 12) or 
activation loop (exon 18);11 the D842V substitution in 
exon 18, is highly resistant to imatinib. GIST tumours 
with  PDGFRA  mutations  tend  to  be  of  epitheliod 
morphology, display weak or no CD117 staining, and 
are usually localized to the stomach.12 The remaining 
10%–15% of GIST tumours lack known mutations 
and their pathophysiology is unclear. Possible mecha-
nisms of oncogenesis in so called wild type tumours 
include: mutations involving IGF1R or BRAF, inacti-
vation of KIT-inhibitory phosphatases, up-regulation 
of the KIT ligand, and KIT heterodimerization with 
other activated receptor-tyrosine kinase proteins.13
Carney  Triad  is  characterized  by  GIST,  extra-   
  adrenal paragangliomas, and pulmonary chondromas.14   
GIST associated with Carney Triad share clinical and 
pathologic features with paediatric GIST and are dis-
tinctly different from adult GIST; patients are typi-
cally young females with multifocal tumours, lack 
KIT and PDGFRA mutations, and respond less often 
to  imatinib.14  Succinate  dehydrogenase  (SDH),  an 
enzyme bound to the inner mitochondrial membrane 
that is involved in the Krebs cycle, is a tumor sup-
pressor  gene.  Inactivating  mutations  of  SDH  have 
been associated with GIST and paraglioma tumours 
(so-called  Carney-Stratakis  syndrome).15  Gill  and 
colleagues were the first to demonstrate that pediatric 
and   Carney-Stratakis associated GIST tended to have 
negative staining for SDH.15 Janeway and colleagues 
detected SDH germline mutations in 4 of 34 (12%) 
patients with wild-type GIST by immunohistochem-
istry.16 This observation is important as SDH protein 
expression detected by   immunohistochemistry could Treatment of GIST with Imatinib Mesylate
Clinical Medicine Insights: Oncology 2011:5  367
be a cost effective method of identifying a proportion 
of wild-type patients.
Imatinib mesylate was initially developed for the 
treatment of chronic myelogenous leukemia, (CML), 
due to its ability to inhibit the BCR-ABL fusion   protein. 
The  phase  III  International  Randomized  Interferon 
versus  STI571  (IRIS)  study  compared  clinical  effi-
cacy of imatinib versus interferon and cytarabine for 
newly diagnosed chronic-phase CML.17 Monotherapy 
with imatinib proved superior to standard therapy with 
improved hematologic and cytogenetic response rates, 
longer  progression-free  survival,  and  lower  toxicity. 
This success prompted use of imatinib therapy in GIST. 
In vitro GIST cell lines with mutant KIT and PDGFRA 
treated with imatinib demonstrate reduced MAP kinase, 
PI3K dependent Akt activity, and enhanced apoptosis.18 
Importantly, the extent of KIT immunostaining does 
not seem to correlate with either the type of KIT muta-
tion or the likelihood of response to imatinib, although, 
immunonegative or weakly staining tumours are more 
likely to be KIT wild type.19
pharmacokinetics
Absorption
Imatinib is formulated in hard capsules or tablets as 
a salt (imatinib methane sulfonate, molecular weight: 
589.7 g/mol).27 Imatinib is a quadrivalent base and read-
ily dissolves in solution with a pH of 5.5; this property 
contributes to the excellent bioavailability of 98%.21 
The predominant location of imatinib absorption is 
unknown and reports of patients with resected small 
bowel and rectum had lower plasma imatinib   levels.22 
Food has no relevant impact on the rate or extent of 
bioavailability. After oral administration, the maximal 
plasma concentration of approximately 1.6 µg/mL is 
reached after 1.5–6 hours.20 In the steady state, peak 
plasma  concentration  (Cmax)  and  area  under  the 
concentration time curve (AUC) are 2.9 µg/mL and 
61.9 µg. h/mL, respectively.20 Considerable interindi-
vidual variability of pharmacokinetics at steady state 
has consistently been observed, with a coefficient of 
variation for AUC of 40%. In CML patients, there is 
a dose proportional increase in AUC from time 0 to 
24 hours for doses ranging from 25 mg to 1000 mg.21
Distribution
Imatinib  undergoes  rapid  and  extensive  distribu-
tion into tissues, but does not cross the blood brain 
  barrier  in  sufficient  concentrations.26  Over  95%  of 
serum imatinib is protein bound either to albumin 
or α1-acid glycoprotein (AAG.) Only the unbound 
portion of imatinib is biologically active.26 As AAG 
is an acute phase reactant and may fluctuate during 
the course of the disease, it has been used to explain 
interindividual variability in imatinib clearance and 
hematologic toxicity.23
Metabolism
Imatinib  is  metabolised  by  the  cytochrome  P450 
(CYP) 3A4 enzymes in the liver, with minor contri-
butions  from  CYP1A2,  CYP2D6,  CYP2C9.26  The 
major  metabolite  formed,  CGP74588,  has  similar 
biologic potency to imatinib and represents approxi-
mately 20% to 25% of the parent drug level at steady-
state in patients with GIST. Co-ingestion of particular 
medications  and  foods,  have  significant  effects  on 
imatinib metabolism. Drugs such as ketoconzaole and 
erythromycin and nonpharmalogic agents like grape-
fruit juice inhibit CYP 3A4 enzymes and raise ima-
tinib plasma concentrations.27 Conversely, inducers 
of CYP3A4 enzyme activity such as dexamethasone, 
phenytoin, rifampicin, and St. John’s Wort lower ima-
tinib plasma levels.25 Equally important, imatinib can 
increase Cmax and AUC of CYP 3A4 substrates such 
as simvastatin and cyclosporine, therefore a careful 
inventory of a patient’s medications is vital.27
Elimination
Imatinib has a terminal half-life of 19 hours (range, 
14–23 hours).24 Gschwind and colleagues collected 
detailed  information  on  excretion  of  imatinib  by 
administration  of  radiolabelled  drug  into  healthy 
volunteers.28 After one week from ingestion of 14C-
radiolabelled  imatinib,  80%  of  the  dose  had  been 
excreted; the predominant mode of elimination was 
fecal (67%) with a minority being excreted via the 
kidneys  (13%).28  In  imatinib  treated  patients  with 
chronic myeloid leukemia, drug clearance has been 
noted to increase with increasing body mass index.29
pharmacokinetics (pK) differences  
in GIST vs. CML patients
The PK properties of imatinib in patients with CML 
and GIST are similar. Altered absorption due to GIST-
related surgeries in the stomach and small intestine 
or  altered  metabolism  secondary  liver  metastases Ksienski
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might explain some of the differences.26 The Cmax 
of imatinib at steady state in patients with GIST is 
2.9 µg/mL compared with 2.3 µg/mL in patients with 
CML.24 Also,  the  rate  of  clearance  for  imatinib  is 
approximately 8% lower in patients with GIST than 
in patients with CML.26
Dose adjustments for renal  
and hepatic insufficiency
Gibbons et al recently published a phase I study of 
patients with unresectable or metastatic GIST and 
varying  degrees  of  renal  impairment.30  Of  sixty 
accrued  patients,  14  had  normal  renal  function 
  (creatinine clearance, CrCL over 59 mL/min), 22 had 
mild  renal  impairment  (CrCL  40  to  59  mL/min; 
group), 22 had moderate dysfunction (CrCL 20 to 
39  mL/min),  and  2  had  severe  renal  impairment 
(CrCL less than 20 mL/min). Intraindividual dose 
escalation  was  permitted  if  no  response  or  dis-
ease  progression  was  observed,  in  the  absence  of 
dose limiting toxicity (DLT). A maximum tolerated 
dose was not reached in the trial. However, serious 
adverse events were more common in patients with 
renal dysfunction. Imatinib exposure, as expressed 
by dose-normalized AUC0–∞ (area under the curve 
from 0 to infinity) on day 1 and AUC0–24 (AUC from 
0 to 24 hours) on day 15, was significantly greater in 
patients with impaired renal function than in those 
with normal renal function. The authors theorize that 
this phenomenon related to lower hepatic CYP activ-
ity and increase levels of AAG in patients with renal 
impairment.
Ramanathan conducted a similar phase I study of 
patients with liver dysfunction and various advanced 
malignancies (most commonly colorectal cancer or 
hepatocellular carcinoma).31 Hepatic dysfunction was 
classified by National Cancer Institute Organ Dys-
function Working Group criteria using serum aspar-
tate aminotransferase and total bilirubin. Unlike the 
previous study, no intrapatient dose escalation was 
allowed. Dose escalation occurred until two or more 
patients had DLT at a particular dose level. Plasma 
pharmacokinetics and urinary excretion of imatinib 
and its metabolite CPG74588 were similar regardless 
of liver function. The maximum tolerated dose (MTD, 
defined as one dose level below DLT) of imatinib for 
patients  with  mild  liver  dysfunction  was  500  mg. 
While MTD was not determined for the   moderate 
and  severe  liver  dysfunction  groups,    imatinib  was 
tolerated up to 300 mg/d in both groups. As such, 
the authors suggest the initial dose for patients with 
hepatic impairment should be 300 mg per day and 
increased to 400 mg per day if there is no evidence of 
adverse effects.
Radiologic Assessment  
of Treatment Response
Standardized  classification  systems  such  as  South-
western  Oncology  Group  (SWOG)  criteria  and 
Response  Evaluation  Criteria  in  Solid  Tumors 
(RECIST), are based on uni- or bidimensional changes 
in tumor size. At the cellular level, GIST respond-
ing to treatment may undergo necrosis, intratumoral 
haemorrhage, or   myxoid degeneration regardless of 
volumetric   changes.32 Radiologic correlates of posi-
tive response to treatment can include: disappearance 
of enhancing nodules and tumor vessels, enhanced 
tumor  homogeneity  and  hypoattenuation,  or  dark-
ening of the tumor due to decreased tumor density. 
Moreover, the time to onset of response can evolve 
slowly over months to years; in B2222, one quarter 
of patients required 5.3–39 months to reach SWOG-
defined response.7
Positron emission tomography using 18-fluoro-
deoxyglucose (18FDG PET) is sensitive in detect-
ing both early response to imatinib and predicting 
long-term  outcomes  in  patients  with  metastatic 
GISTs.33 Van den Abbeele et al demonstrated that 
absolute value for SUVmax of 3.4 and a 40% reduc-
tion in SUVmax one month after initiation of treat-
ment was predictive of improved time to treatment 
failure.33 Unfortunately, routine use of PET is lim-
ited by a lack of scanner availability and cost con-
straints.  Choi  and  colleagues  noted  that  imatinib 
sensitive  gastrointestinal  stromal  tumours,  dem-
onstrate decreases in tumoral density on computed 
tomography (CT).34 The so-called ‘Choi criteria’, 
a 10% decrease in unidimensionaltumor size or a 
15% decrease in tumor density on contrast-enhanced 
CT correlate well with positive response by PET 
and is more predictive of time to tumor progression 
than RECIST.35 As such, it should be remembered 
that all of the trials described below utilized radio-
logic response criteria designed for traditional cyto-
toxic drugs and probably resulted in lower reported 
response rates.Treatment of GIST with Imatinib Mesylate
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Efficacy
preclinical
Using a KIT expressing human myeloid leukemia cell 
line, M-07e, Heinrich et al determined that 100 nmol/L 
of  imatinib  decreased  ligand  stimulated  tyrosine 
kinase phosphorylation by 50%.18 Furthermore, ima-
tinib inhibited stem cell factor dependent growth in a 
dose dependent manner. Tuveson et al created a GIST 
cell line with a missense mutation (K642E) in exon 
13 causing constitutive KIT activation; after incuba-
tion with imatinib, there was a decrease in level of 
phosphorylated tyrosine, amelioration of cell prolif-
eration, and evidence of apoptosis.36
Unresectable/metastic GIST
The initial pilot study of imatinib in advanced GIST 
occurred in the year 2000 with a Finnish patient.37 
After presenting with abdominal pain in 1996, she 
underwent  curative  resection  of  two  large  gastric 
GISTs.  Two  years  later  she  developed  metasta-
ses  to  the  peritoneum  and  liver  which  progressed 
despite  multiple  lines  of  chemotherapy.  Based  on 
clinical  experience  with  CML,  the  Finnish  patient 
received  imatinib  at  400  mg  daily.  Positron  emis-
sion tomography performed 1 month after initiation 
of   treatment, showed no abnormal uptake of 18FDG 
in the previously metabolically active liver lesions. 
After 8 months of treatment, six of twenty-eight liver 
metastases  were  no  longer  detectable  by  magnetic 
resonance imaging (MRI). Repeated biopsies during 
the course of treatment revealed a reduction in tumor 
cell density, myxoid degeneration, and scarring. The 
drug was well tolerated with minimal toxicity and 
response continued for two years.6 In retrospect, as 
the tumor contained a KIT exon 11 mutation, there 
was a high likelihood of treatment response. The suc-
cessful treatment of the first patient with metastatic 
GIST  sparked  a  rapid  succession  of  pivotal  trials, 
described in Table 1.
The European Organization for Research and Treat-
ment of Cancer subsequently initiated a phase I   trial.38   
Of  forty  patients  accrued,  36  had  gastrointestinal 
stromal tumours; dosing levels ranged from 400 mg 
to 1000 mg daily. Treatment with 500 mg bid led to 
dose-limiting toxicities in five patients: severe nau-
sea, vomiting edema or rash. Of note, three patients 
experienced  intratumoral  bleeding.  25  of  36  GIST 
patients  met  criteria  for  an  objective  response, 
with  nineteen  (53%)  having  a  confirmed  partial 
response  and  seven  (19%)  had  stable  disease.  In 
addition, response assessed by PET imaging 8 days 
after  treatment  began,  predicted  objective  response 
Table 1. Summary of key GIST trials in metastatic and adjuvant setting.
Trial phase/ 
setting
primary 
endpoint
Treatment 
(number patients)
ORR pFs Overall 
survival
comment
B22227 II, 
Metastatic
Orr 400 mg daily (n = 73) 
600 mg daily (n = 74)
78.9% 
78%
20 months* 
26 months*
55%** 
55%**
No statistically 
significant 
difference
EOrTC39 II, 
Metastatic
Orr 400 mg bid (n = 27) 71% 73%*** n/a
US-CDN45 III, 
Metastatic
OS 400 mg daily (n = 345) 
400 mg bid (n = 349)
45% 
45%
18 months* 
30 months*
55 months**** 
51 months****
No statistically 
significant 
difference
EU-AUS46 III, 
Metastatic
pFS 400 mg daily (n = 473) 
400 mg bid (n = 473)
45% 
45%
50%*** 
56%***
85%***** 
86%*****
Statistically 
significant 
pFS
ACOSOG 
Z900156
III, 
Adjuvant
rFS 400 mg daily × 
1 year (n = 359) 
No adjuvant therapy
n/a 98%+ 
 
83%+
98.6%++ 
 
97.7%++
Statistically 
significant 
rFS
SSG xvIII/ 
AIO59
III, 
Adjuvant
rFS 400 mg daily × 
3 years (n = 200) 
400 mg bid × 
1 year (n = 200)
n/a 65.6%+++ 
 
47.9%+++
92%++++ 
 
81.7%++++
Statistically 
significant 
rFS and OS
notes: *Median progression free survival; **5 year overall survival; ***1 year progression free survival; ****median overall survival; *****1 year overall 
survival; +1 year rFS; ++1 year overall survival; +++5 year rFS; ++++5 year OS.Ksienski
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by computed tomography after 8 weeks. Given the 
  preliminary evidence of clinical efficacy and   tolerable 
safety profile, three phase II studies were launched: 
the  B2222  US-Finland  study,7  EORTC  Soft Tissue 
and Bone Sarcoma Group trials,39 and B1202   Japanese 
study.40
The EORTC Soft Tissue and Bone Sarcoma phase II 
trial examined the response rate and time to progres-
sion of various sarcomas to the maximum tolerated 
dose of imatinib (400 mg bid).39 Of 27 patients with 
GIST, one (4%) experienced a complete remission, 
eighteen (67%) partial remission, five (18%) stable 
disease, and three (11%) disease progression. 73% of 
GIST patients were free from progression at 1 year. 
Side-effects were tolerable and no patient discontin-
ued the drug due to adverse events.
The  B2222  US-Finland  study  randomized  147 
patients with unresectable or metastatic GIST to ima-
tinib 400 mg (n = 73) or 600 mg daily (n = 74).7 Patients 
on the lower dose experiencing progression were permit-
ted to crossover to 600 mg daily and ultimately 400 mg 
twice  daily.  With  63  months  follow-up,  the  overall 
response rates (68.1% overall, 68.5% [400 mg], 67.6% 
[600 mg]), median progression free survival (24 months 
overall, 20 months [400 mg], 26 months [600 mg]), 
and 1-year overall survival (88% for all patients) were 
similar between the treatment arms. Interestingly, one-
quarter of patients required over 5 months to achieve 
either a partial or complete response as assessed by CT 
or MRI; with longer follow-up 23 patients (16% of all 
patients) initially classified as having progressive stable 
disease, achieved either a partial or complete response. 
Furthermore,  overall  survival  was  identical  amongst 
patients who achieved either stable disease or a partial 
response (5 year overall survival, 55%). These obser-
vations  highlight  the  pitfalls  of  traditional  response 
criteria which measure volumetric changes as oppos-
ing to metabolic changes with PET scans. Now, with a 
median follow-up of 9.4 years, 26 pts (17.7%) remained 
on treatment and 9-year OS rate for all patients was 
35%.41 Baseline tumor bulk, as separated by quartiles, 
was predictive of long term overall survival: 9-year OS 
for patients in the lowest quartile was 53% compared to 
23% for patients with the largest tumours.
Archival  pre-treatment  pathology  specimens  suit-
able for genotyping were available from 127 of the 
147 patients enrolled in the B222 study: 112 had KIT 
mutations (85 in exon 11 and 23 in exon 9), 6 had   
PDGFRA mutations, and 9 were wild-type.42 Patients 
whose tumor expressed an exon 11 mutant KIT were 
much more likely to have a partial response with imatinib 
therapy as compared to either exon 9 mutants or wild-
type/PDGFRA (83.5%, 47.8%, and 0% respectively). In 
addition to being a predictive factor, KIT exon 11 muta-
tion status was also a prognostic factor as median over-
all survival was superior compared to KIT exon 9 or 
other genotypes (63 months, 44 months, and 26 months 
respectively).42 Imatinib therapy was approved for met-
astatic or unresectable GIST in November 2001 by the 
European Medical Association (EMA) and in February 
2002 by the FDA, based on the findings of the B222 
US-Finland and EORTC studies.43,44
Similar to the B2222 US-Finland study, the B1202 
study was an open label randomized phase 2 study 
of patients with advanced GIST receiving imatinib at 
a dose of 400 mg/d (n = 28) or 600 mg/d (n = 46).40 
Again, no significant difference was found in response 
rate (69% overall), median progression free survival 
(96 weeks overall), and 3-year overall survival (73.6% 
overall) by dose. Side-effects were mild and included 
nausea (78% overall patients), diarrhea (70%), derma-
titis (62%), facial edema (61%), and emesis (54%).
Due to lingering uncertainty regarding optimal dose 
for patients with advanced GIST (ie, 400 mg once or 
twice daily), two phase III trials were launched: the 
first  conducted  jointly  in  Europe  and Australia  by 
EORTC,  Italian  Sarcoma  Group,  and  Australasian 
Gastrointestinal Trials Group (referred to as EU-AUS) 
and the second conducted in the United States and 
Canada by Southwest Oncology Group, Cancer and 
Leukemia  Group  B,  National  Cancer  Institute  of 
Canada,  and  Eastern  Cooperative  Oncology  Group 
(referred to as US-CDN).45,46 The primary endpoint of 
the US-CDN trial was overall survival; the investiga-
tors accrued an impressive 746 patients with unresect-
able or metastatic GIST in 9 months. With a median 
follow-up  time  of  4.5  years,  there  was  no  statisti-
cally significant difference by dose in response rate 
(45% confirmed complete and partial responses in both 
arms), progression free survival (18 months [400 mg] 
and  20  months  [600  mg]),  or  median  overall  sur-
vival (55 months [400 mg] and 51 months [600 mg]). 
After progression on standard-dose imatinib, 33% of 
patients who crossed over to the high-dose imatinib 
regimen achieved either a partial response or stable 
disease. Serious adverse events and deaths were more Treatment of GIST with Imatinib Mesylate
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common in the high-dose imatinib arm, as were dose 
delays and reductions. Tumor samples were obtained 
from 447 patients of whom 368 were CD117 posi-
tive GIST.47 308 tumours had KIT mutations (269 in 
exon 11 and 31 in exon 9), 4 tumours had mutations 
in PDGFRA exon 18, and 56 were wild-type. Muta-
tion status was found to be both prognostic and pre-
dictive of response to imatinib. KIT exon 11 mutation 
status as opposed to exon 9 or wild-type genotype 
correlated  to  higher  response  rates  (71.7%,  44.4%, 
and 44.6%, respectively), improved progression free 
survival (24.7 months, 16.7 months, and 12.8 months) 
and median overall survival (60 months, 38.4 months, 
and 49 months). Treatment with high dose imatinib in 
patients with KIT exon 9 yielded improved response 
rates (CR/PR, 67% vs. 17%) but no statistically signif-
icant difference in progression free survival or median 
overall survival.
The EU-AUS study accrued 946 patients and had 
a similar protocol to the US-CDN study, but the pri-
mary endpoint was progression free survival.46 At 
initial publication with a median follow-up of approx-
imately 25 months, progression free survival was 
slightly longer in the patient group receiving higher 
dose as opposed to standard dose imatinib (56% vs. 
50%, P = 0.026). However, after a median follow-up 
time of 40 months, the difference in progression free 
survival was no longer statistically significant.48 The 
higher imatinib dose caused increased adverse effects 
such as edema, rash, fatigue nausea, bleeding, diar-
rhea, and anemia. Of 247 patients with documented 
progression on standard dose imatinib, 133 patients 
crossed-over to the higher dose; impressively 29% 
achieved either a partial response or disease stabili-
zation and 18% were still progression free at 1 year 
after cross-over. Debiec-Rychter et al published an 
accompanying paper attempting to correlate GIST 
genotype with clinical efficacy.49 KIT exon 9 muta-
tion status had prognostic (190% increased relative 
risk of death compared to patients with KIT exon 
11 mutation) and predictive (61% relative decrease 
in risk of progression when treated with high dose 
imatinib) value. Interestingly, response to high dose 
imatinib upon progression was high in patients with 
wild type or KIT exon 9   mutations as opposed to KIT 
exon 11 mutants (83%, 57%, and 7%, respectively).
As  selection  criteria,  protocol  treatment,  and 
  follow-up were similar in the EU-AUS and US-CDN 
studies, a meta-analysis including all 1640 patients 
was undertaken-metaGIST.50 In the pooled data set, 
a small but statistically significant improvement in pro-
gression free survival benefit at 3 years (34% [400 mg 
bid] vs. 30% [400 mg daily]) was observed. There 
was no difference in overall survival in the standard 
versus higher dose treatment arms. Seven factors had 
adverse prognostic value on multivariate analysis for 
overall survival: high neutrophil counts, poor perfor-
mance status, advanced age, low albumin level, prior 
chemotherapy, large tumor size, and male sex.   Having 
a KIT exon 9 mutation was the only factor predic-
tive of benefit for high dose imatinib on multivariate 
analysis. As a result, for unresectable or metastatic 
GIST both the NCCN and ESMO guidelines recom-
mend a dose of 800 mg daily for patients with KIT 
exon 9 mutation.51,52
Adjuvant
Despite resection of all macroscopic GIST, five year 
survival is 54% and disease free survival is 45%.53 
Accurate risk stratification is crucial for the selec-
tion of patients most likely to benefit from adjuvant 
imatinib  therapy;  factors  that  predict  relapse  after 
surgical resection include tumor size, mitotic index, 
primary site, microvessel density, and presence and 
site of KIT mutation.87 The Gold nomogram predicts 
recurrence free survival at two and five years after 
surgery based on tumour size, location, and mitotic 
index; the predictive ability of the nomogram is supe-
rior to National Institute of Health consensus classifi-
cation system and not statistically different from the 
Miettinen-Lasota/Armed Forces Institute of Pathol-
ogy  classification  system.54  Importantly,  the  Gold 
nomogram has  never been  prospectively evaluated 
and the agreement on mitotic index between patholo-
gists varies.
Nilsson  and  colleagues  treated  23  consecutive 
patients at a single centre with completely resected 
GIST at high risk for relapse (based on a risk score 
of tumor size and the Ki-67 maximum proliferative 
index)  with  one  year  of  imatinib  400  mg  daily.55 
After a median follow-up of three years, only one 
of the 23 (4%) patients developed recurrent disease 
  compared to 32 out of 48 patients (67%) in the his-
torical control group. The American College of Sur-
geons Oncology Group (ACOSOG) Z9000 conducted 
a  single-arm  phase  II  multicenter  trial  of  adjuvant Ksienski
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therapy for 107 patients with high risk resected GIST 
(tumor size $10 cm, tumor rupture, or ,5 peritoneal 
metastases).88  Treatment  with  standard-dose  ima-
tinib (400 mg daily) for 1 year was associated with 
improved overall survival, with rates of  99%, 97% and 
97% after 1, 2 and 3 years of follow-up, respectively.
The ACOSOG Z9001 trial, a multinational phase III 
trial, examined differences in recurrence free survival 
(defined as the time from randomization to the devel-
opment of tumor recurrence or death due to any cause) 
based on assignment to 1 year of 400 mg imatinib 
daily (n = 359) or placebo (n = 354).56 All patients 
were at least 18 years if age, had KIT-positive GIST 
tumours at least 3 cm in size, and had undergone 
complete  gross  tumor  resection  within  84  days  of 
randomization. Importantly, patients were stratified 
by tumor diameter but not mitotic rate, tumour site, or 
rupture on the grounds that these prognostic indica-
tors have not been validated prospectively. Treatment 
was  stopped  prematurely  in  184  (25.8%)  patients; 
discontinuation  was  more  likely  due  to  adverse 
events in the imatinib arm (P , 0.0001) and tumor 
recurrence in the placebo arm (P , 0.0001). With a 
median   follow-up of 19.7 months, the one-year RFS 
was 98% (95% CI 0.96–1.00) on the imatinib arm 
versus 83% (95% CI 0.78–0.88) on the placebo arm; 
the overall hazard ratio was 0.35 (95% CI 0.22–0.53) 
with a P-value ,0.0001. At the time of reporting, 
there was no significant treatment difference in over-
all  survival  (HR  =  0.66  [95%  CI  0.22–2.03]).  On 
multivariate analysis, factors predictive of recurrence 
in the placebo group were mitotic rate (P , 0.0001), 
tumor size (P , 0.0026), small bowel location (vs. 
gastric location; P , 0.0267), and KIT exon 11 muta-
tions  (vs.  wild  type;  P  =  0.042).  Subgroup  analy-
sis revealed that patients with large tumors (greater 
than 10 cm in diameter) derived the greatest benefit 
from imatinib treatment. Based on the findings of the 
ACOSOG Z9001 trial, the EMA and FDA approved 
adjuvant imatinib as a treatment option in patients at 
substantial risk of relapse.57,58
One of the most compelling questions regarding 
adjuvant treatment of resected GIST, is the optimal 
duration  of  imatinib.  The  Scandinavian    Sarcoma 
group’s  SSG  XVIII/AIO  trial  is  an  open  label 
phase  III  trial  comparing  1  year  (n  =  200)  versus 
3 years (n = 200) of imatinib therapy after surgical 
  resection.59 All patients were high risk according to 
the modified Consensus criteria (based on tumor size, 
mitotic  count,  and  tumor  rupture).60  5  year  recur-
rence  free  survival  was  significantly  longer  in  the 
group treated for 3 years (65.6% [3 years] vs. 47.9% 
[1 year]); importantly, overall survival was also signif-
icantly higher at 5 years with longer duration of treat-
ment (92% [3 years] vs. 81.7% [1 year]).   However, 
27 patients assigned to 3 years of imatinib discon-
tinued treatment early due to adverse events, while 
only 15 patients treated for 1 year stopped treatment 
due to side-effects. All but two patients in the entire 
trial were free of any adverse effects; grades 3 and 4 
adverse events more common in the group treated for 
longer duration (20% [1 year] vs. 33% [3-years]).
The SSG XVIII/AIO trial raises a number of sig-
nificant issues. First, high risk according to the modi-
fied consensus criteria, includes patients with a risk of 
relapse ranging from 34% to 100%; it remains uncer-
tain if all such patients actually benefit from adjuvant 
therapy, or if a higher cut-off value could be used. 
Second, in the ACOSOG Z9001 trial patients treated 
with one year of imatinib therapy experienced a high 
rate of relapse approximately six months after therapy 
cessation; whether longer duration of adjuvant ther-
apy might actually increases overall survival or sim-
ply delays relapse, will become clearer with longer 
follow-up. Last, it is uncertain if KIT exon 9 mutants 
might benefit from imatinib 800 mg daily as is the 
case with advanced disease.
Neoadjuvant
At  present,  published  literature  on  neoadjuvant 
imatinib  therapy  is  limited  to  surgical  series,  two 
phase II trials, and retrospective subgroup analysis 
of a phase III trial. McAuliffe and colleagues ran-
domized 19 patients to receive preoperative imatinib 
600 mg daily for 3, 5, or 7 days followed by two years 
of imatinib at a similar dose; primary endpoint of the 
phase II study was tumor cell apoptosis and secondary 
endpoints were patient safety, disease free survival, 
and radiographic response.61 Compared to historical 
surgical controls, there was no difference in surgical 
morbidity.  Approximately two thirds of patients demon-
strated  responses  as  seen  on  PET  scan  or  decreased  tumor 
blood flow assessed by dynamic CT. Interesting, while 
the degree of apoptosis increased with longer dura-
tion of preoperative treatment, this did not correlate 
with prolonged disease free survival. In the phase II Treatment of GIST with Imatinib Mesylate
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Radiation Therapy  Oncology  Group  013/American 
College of Radiology Imaging Network 6665, preop-
erative imatinib 600 mg daily for 2 to 3 months was 
followed by postoperative therapy for two years at the 
same dose.62 In the subgroup of patients with locally 
advanced disease (defined as tumors at least 5 cm in 
diameter) 2 year overall survival and progression free 
survival was 93% and 83% respectively. A retrospec-
tive sub-analysis of the BFR14 phase III trial, evalu-
ated the efficacy of neoadjuvant imatinib in patients 
with locally advanced GIST (as defined by local mul-
tidisciplinary team).63Nine of the 25 assessed patients 
underwent complete resection following a median of 
7.3 months of imatinib treatment; six of these patients 
had sufficient tumor shrinkage to facilitate resection 
while three patients went to surgery due to early signs 
of progression. A superior progression free survival 
was  observed  in  patients  who  underwent  surgical 
resection compared with those who did not who did 
not (not reached vs. 23.6 months, P = 0.0322). The 
optimal role of neoadjuvant imatinib therapy in daily 
practice is unclear at the moment; NCCN guidelines 
recommend initial treatment with imatinib for patients 
with marginally resectable tumours and for those who 
have potentially resectable disease but with the risk 
of significant morbidity.64
side-effects
Virtually all patients treated with imatinib have at 
least one adverse event and 21%–43% experience a 
Grade 3 or 4 adverse events.65 Most side effects occur 
early in the course of treatment and tend to reduce in 
frequency and intensity over time. This phenomenon 
has been correlated with increased imatinib clear-
ance  with  long-term  treatment.66  Utilizing  safety 
data from the EU-AUS phase III study of standard or 
high dose imatinib for advanced GIST, Van Glabbeke 
et  al  determined  patient  and  tumor  characteristics 
that predicted for grade 2 or higher non-hematologic 
toxicities (edema, fatigue, nausea, diarrhea, and skin 
rash) and grade 3 or 4 hematologic adverse effects 
(anaemia and neutropenia).67 High dose was corre-
lated with anaemia and all the previously listed non-
hematologic adverse effects. Female patients were 
more likely to experience edema, fatigue, nausea, and 
diarrhea; this may relate to lower on average weight 
compared to male counterparts, leading to reduced 
clearance and higher AUC.68 In the EU-AUS study, 
advanced  age  was  associated  with  dermatologic 
toxicity and fatigue; lastly, fatigue and nausea were 
more common in patients with a poor performance 
status.
The most common hematologic toxicities are anae-
mia and neutropenia. Unlike neutropenia, anemia is 
dose dependent; in the S0033 phase III trial, about 
20% of patients on standard dose imatinib and 27% 
on high dose imatinib experienced grade 3 or 4 hema-
tologic toxicity.45 Baseline low hemoglobin is a risk 
factor for anemia and neutropenia while on treatment, 
as the AUC is greater than in patients with a normal 
baseline hemoglobin level.
Dermatologic side-effects are common and include 
edema and maculopapular eruptions. Edema occurs in 
about 39%–74.1% of imatinib treated patients and is 
typically localized to the periocular or pedal regions.69 
While the exact physiology is unknown, a common 
explanation is increased capillary permeability and 
extravasation of fluid due to inhibition PDGFR signal-
ling in dermal dendrocytes. Mild cases of periorbital 
edema may be treated with a low-salt diet, topical 
1% hydrocortisone, 0.25% topical phenylephrine, or 
oral diuretics.68 Rarely, severe periorbital edema may 
require drug cessation or surgical intervention with 
bilateral upper eyelid blepharoplasty. Imatinib induces 
self-limited non-specific maculopapular eruptions in 
30%–40%;  classic  drug-associated  skin  manifesta-
tions, such as vasculitis, Stevens-Johnson syndrome, 
and toxic epidermal necrosis are documented in case 
reports.69
As  several  other  tyrosine  kinase  inhibitors  (ie, 
sunitinib) are known to have deleterious effects on 
cardiac function, recent studies have examined poten-
tial cardiotoxicity from long term imatinib therapy. 
Kerkela et al identified ten imatinib treated patients 
with CML who developed heart failure.70 On trans-
mission electron micrographs, mitochondrial abnor-
malities and accumulation of membrane whorls in the 
endoplasmic reticulum (ER) suggested a toxic myo-
pathy. In vitro assays of imatinib treated myocytes 
revealed  activation  of  ER  stress  pathways  leading 
to mitochondrial collapse and apoptosis. While pro-
spective studies are lacking, to date there is no con-
clusive evidence of imatinib directly causing cardiac 
damage  in  humans.  Of  942  treated  patients  in  the 
EU-AUS study, there were 7 documented episodes of 
cardiac failure and 3 deaths due to cardiac events.71 Ksienski
374  Clinical Medicine Insights: Oncology 2011:5
However, excluding patients with pre-exciting car-
diac dysfunction or prior exposure to doxorubicin left 
only 2 patients (0.2% of all treated patients) where 
imatinib was the only potential cause of cardiac fail-
ure. Similarly, Trent el al reviewed cardiac safety data 
of 219 patients with GIST and other sarcomas treated 
with imatinib;72 5 patients had objective evidence of 
cardiac ischemia or chest pain, 2 patients had doc-
umented arrhythmias, and only 1 had objective left 
ventricular dysfunction by echocardiography. Until 
a causal association between imatinib exposure and 
cardiac damage can be excluded, patients with car-
diac disease or risk factors for cardiac failure should 
be monitored carefully and those developing signs or 
symptoms suspicious for cardiac failure are evaluated 
and treated.
Resistance
Approximately 80% of GIST patients with advanced 
disease receive some benefit from imatinib therapy, 
but a significant proportion eventually become resis-
tant with a median time to progression of 2 years. To 
better understand the mechanisms underlying the two 
patterns of resistance, it is important to appreciate the 
three dimensional structure of KIT. The intracellular 
portion of KIT consists of a juxtamembrane domain 
and proximal and distal kinase (including the acti-
vation loop) regions separated by a kinase insertion 
domain. These regions can either be configured in an 
“open/on” conformation which allows ATP to bind or 
a “closed/off ” conformation which facilitates phos-
phorylation  of  substrates.73  Trans-phosphorylation 
of two tyrosine residues in juxtamembrane domain 
(Y568 and Y570) causes: (1) a steric shift allowing 
ATP to bind to the proximal domain (2) release and 
phosphorylation of the activation loop which helps 
maintain  an  “open/on”  conformation.  Imatinib  can 
only attach to the off conformation and functions to 
maintain the receptor in this state. However, most 
KIT mutations and PDGFRA mutations promote the 
open conformation, thereby reducing the efficacy of 
imatinib.
A potentially important mechanism of early resis-
tance  results  from  subtherapeutic  imatinib  plasma 
levels. In a retrospective analysis of 73 patients with 
advanced GIST from the B2222 trial, Demetri et al, 
correlated imatinib trough level (Cmin) on day 29 
with long term outcome.74
Patients in the lowest Cmin quartile ($1,100 ng/mL)   
had  a  significantly  shorter  time  to  progression 
(11.3 months) when compared to patients in the upper 
three quartiles (30.6 months, P = 0.0029). In addition, 
amongst the subset of patients with KIT exon 9 muta-
tion, the objective overall response rate (includes patients 
with complete and partial response and stable disease) 
was inferior in the lowest Cmin quartile compared to 
all others. No significant differences in median overall 
survival was found between different Cmin quartiles.
Acquired  resistance,  unlike  primary  resistance, 
typically  involves  secondary  mutations  (67%  vs. 
10%, respectively) in either the ATP binding pocket 
of the kinase domain (exons 13 and 14) or the kinase 
activation loop (exons 17 and 18).75   Secondary muta-
tions develop more often in tumours with a primary 
exon 11, rather than exon 9 mutated KIT (60% and 
20%  of  the  cases,  respectively). Alternate  mecha-
nisms  of  delayed  resistance  include:  amplification 
of  KIT  or  PDGFRA  gene,  activation  of  alternate 
tyrosine kinases (AXL, or insulin-like growth   factor-1 
  receptor),  efflux  of  intratumoralimatinib  via ABC 
drug pumps.73
patient preferences
While imatinib is well tolerated compared to cyto-
toxic therapy, patients will experience at least mild 
adverse effects. Drug holidays and dose reductions are 
not without risk as discontinuation of imatinib admin-
istration can results in rapid tumor progression. The 
French Sarcoma Group BFR14 study demonstrated 
that interruption amongst patients with disease con-
trol after 1 year of imatinib therapy, yielded a median 
time to progression of 6 months, and most patients 
had  relapsed  1  year  after  treatment  interruption.76 
Feng and colleagues attempted to quantify compli-
ance in imatinib treated patients with CML (n = 286) 
and GIST (n = 34) and reasons for nonadherence.77 
Only 76% of all doses prescribed were filled within 
the first year and 28% of patients required at least a 
30 day drug interruption. On multivariate analysis, 
factors  associated  with  non-compliance  included: 
increasing age, female gender, and patients with more 
cancer complications.
place in Therapy
Although  imatinib  is  unquestionably  effective, 
other treatment options are inevitably necessary as Treatment of GIST with Imatinib Mesylate
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approximately 10%–15% of GIST patients show pri-
mary resistance to imatinib, 50% develop secondary 
  imatinib resistance within 2 years and 4% of patients 
are  intolerant  to  imatinib  therapy.  Metastatectomy 
is useful in a highly selected group of patients. The 
  nodule-within-a-tumor  phenomenon,  is  a  common 
radiologic sign of progression and signifies the emer-
gence of a resistant clone of cells.78 Surgical exci-
sion of a few progressing lesions has yielded positive 
results in nonrandomized studies and imatinib can 
continued to be used to maintain pressure on sensi-
tive clones.79 However, individuals with multifocal 
progression require change in systemic therapy.
Sunitinib  maleate  (SUTENT,  previously  known 
as SU11248; Pfizer, New York, USA) is an oral mul-
titargeted receptor tyrosine kinase inhibitor of KIT, 
PDGFR alpha and beta, vascular endothelial growth 
factor  receptors  (VEGFR-1,  -2  and  -3),  FMS-like 
tyrosine kinase 3, colony-stimulating factor 1 recep-
tor, and the glial cell line–derived neurotrophic fac-
tor receptor.75 Due to its broader spectrum of activity, 
suntinib also causes a different spectrum of poten-
tially serious adverse events such as hypertension, 
hypothyroidism, and heart failure. A phase I/II trial of 
GIST patients after imatinib failure due to resistance 
or intolerance, established a maximum tolerated dose 
of  50  mg/d  for  four  weeks  of  a  six  week  cycle.80 
Of ninety-seven treated patients, 7 (7%) achieved a 
partial response and 35 (46%) had stable disease as 
assessed by CT scan; dose limiting toxicities were 
fatigue, diarrhea, and nausea. Detailed genotype anal-
ysis of all treated patients by Heinrich and colleagues 
revealed improved outcomes in KIT exon 9 compared 
to exon 11 mutant tumours in terms of response rate 
(37% vs. 5%), progression free survival (19.4 months 
vs. 19.0 months) and overall survival (26.9 month 
and 12.3 months). Median progression free survival 
and overall survival were similarly improved in suni-
tinib treated wild type tumours in comparison to exon 
11 mutant tumors.81
A placebo controlled randomized trial of sunitinib 
therapy  for  advanced  GIST  in  patients  resistant  to 
or intolerant of imatinib, demonstrated an improved 
median  time  to  progression  (27.3  weeks  for  suni-
tinib versus 6.4 weeks for placebo) and progression 
free  survival  (24.1  weeks  and  6  weeks).82  Median 
overall  survival  using  the  Kaplan-Meier  technique 
between  sunitinib  treated  patients  (73.9  weeks) 
and  those  receiving  placebo  (64.9  weeks)  was  not 
statistically  significant. The  most  common  grade  3 
adverse events were palmar plantar erythrodysesthesia, 
fatigue, and diarrhea; 19 (9%) sunitinib treated patients 
discontinued therapy because of adverse events.
Enrolment in a clinical trial is recommended for 
patients with GIST who have progressed on imatinib 
and sunitinib; Table 2 lists many such agents cur-
rently being tested. In particular, a number of second 
generation tyrosine kinase inhibitors and novel pro-
teins are being tested. Nilotinib (Tasigna®, Novartis 
Pharma  AG,  Basel,  Switzerland)  was  formulated 
based on the crystal structure of imatinib, to have 
high  efficacy  against  imatinib  resistant  BCR-ABL 
mutants.83 In vitro studies have shown nilotinib to be 
a potent inhibitor of several KIT mutant cell lines: 
exon 11 KITV560del, exon 13 KITK642E, and double muta-
tions involving KIT exons 13 or 17.83 The Evaluat-
ing Nilotinib Efficacy and Safety in Clinical Trials 
(ENEST g3) compared nilotinib with best support-
ive care. Importantly best supportive care comprised 
a heterogeneous group of patients including: those 
still receiving imatinib (n = 54), sunitinib (n = 23), 
and patients who had progressed on both (n = 6).84 
No statistically significant differences in progression 
free survival or overall survival were found between 
the nilotinib and control arms. An exploratory post 
hoc  analysis  indicated  that  nilotinib  provided  a 
4-month improvement in median OS in true third 
line patients (median overall survival, 57.8 weeks 
nilotinib  vs.  40  weeks).  As  a  result,  a  current   
Table  2.  Selected  agents  under  study  and  their  main 
targets.
Nilotinib (AMN107) KIT, pDGFrA/B, Abl
Sorafenib (BAY 43-9006) KIT, pDGFrB, vEGFr 2/3, 
raf, Flt-3, rET
vatalanib (pTK787/
ZK222584)
KIT, pDGFA/B, vEGFr1-3
IpI-504 (retaspimycin) HSp90 inhibitor
STA-9090 HSp90 inhibitor
B11B021 HSp90 inhibitor
Bortezomib 26S proteosome inhibitor
Everolimus (rAD001) mTOr inhibitor
ridaforolimus (Ap23573) mTOr inhibitor
vorinostat Histone deacetylase inhibitor
CUDC101 Histone deacetylase inhibitor
panobinostat Histone deacetylase inhibitor
pF-04691502 pI3K, mTOr inhibitorKsienski
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phase  III  study  is  underway,  comparing  nilotinib 
versus placebo in adult patients with advanced GIST 
resistant to imatinib and sunitinib.
Heat shock proteins (HSP) are molecular chaper-
ones involved in posttranslational folding, stability, 
activation and maturation of many proteins integral 
to signal transduction and cell cycle progression.85 
HSP90 is essential for the stability and the function 
of many oncogenic proteins including: Her2, BCR-
ABL,  AKT/PKB,  C-RAF,  VEGFR,  and  FLT3.  In 
GISTs,  it  was  hypothesized  that  HSP90  inhibition 
would dampen growth signals emanating from the 
mutated receptor and ultimately inhibit cell growth. 
However, efficacy in clinical trials has been mixed 
and a phase III study with IPI-504, a water-soluble 
HSP90  inhibitor,  was  terminated  early  due  to  the 
occurrence of four on treatment deaths in the study 
drug arm.86
conclusion
Just over a decade ago, GIST were a poorly charac-
terized mesenchymal neoplasm with a guarded prog-
nosis due to chemo and radioresesistance. However, 
with discovery that imatinib targeted mutant KIT 
and  PDGRFA  receptors,  median  overall  survival 
  tripled. The B2222 study, with 35% of patients alive 
at 9 years of follow-up, highlights the potential of 
long term survival. In fact, GIST has become a model 
for  the  development  of  other  targeted  therapies. 
  However, management paradigms will continue to 
evolve as ongoing studies accrue. For instance, the 
optimal duration of adjuvant treatment at the present 
time is unknown. In the metastatic setting, further 
research will need to focus on management of low 
grade adverse effects which effect compliance in the 
long term. Last, the place of other tyrosine kinase 
inhibitors  and  novel  proteins  which  target  down-
stream  signal  transduction  pathways  in  treatment 
algorithms will need to be clarified.
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